A symposium featuring discussion of patient case studies and key clinical trial data by renowned clinical experts providing their perspectives on recent advances in the treatment of multiple myeloma.

View the Video and Download Slides (https://www.clinicaloptions.com/oncology/programs/2022/myelomaheme2022)

Agenda:

Welcome and introduction

Patient Case Studies with short didactic and panel discussions

• How do you determine risk of progression for smoldering MM?
• When do you consider therapy for patients with smoldering MM?
• Introduction to the 2023 MM Care Algorithm: Diagnosis
• What induction therapy is optimal for patients with newly diagnosed MM?
• What should the ideal duration of therapy be for first-line MM?
• Introduction to the 2023 MM Care Algorithm: Newly Diagnosed MM
• When should you start treatment at first relapse?
• What strategy do you use to select therapy at first relapse?
• Introduction to the 2023 MM Care Algorithm: Treatment at First Relapse
• How do you select therapy for an “average” patient who has experienced multiple relapses?
• Case variation: What patient and disease factors would change your treatment approach?
• What therapy do you consider for patients after BCMA-targeted treatment?
• Introduction to the 2023 MM Care Algorithm: Treatment for Heavily Pretreated Disease

Program summary and closing

Faculty:

Brian G.M. Durie, MD
Medical Director, AMyC
Co-Chair Myeloma Committee, SWOG
Chairman, International Myeloma Foundation
Specialist in Multiple Myeloma and Related Disorders
Cedars-Sinai Outpatient Cancer Center
Los Angeles, California

Shaji K. Kumar, MD
Mark and Judy Mullins Professor of Hematological Malignancies
Chair, Myeloma Amyloidosis Dysproteinemia Group
Consultant, Division of Hematology
Mayo Clinic
Rochester, Minnesota

Thomas G. Martin, MD
Clinical Professor of Medicine
Associate Director, Myeloma Program
University of California, San Francisco Medical Center
San Francisco, California

Philippe Moreau, MD
Professor of Clinical Hematology
Head, Hematology Department
University Hospital Hôtel-Dieu
Nantes, France

S. Vincent Rajkumar, MD
Edward W. and Betty Knight Scripps
Professor of Medicine
Mayo Clinic
Rochester, Minnesota

Jesús F. San-Miguel, MD, PhD
Director of Clinical and Translational Medicine
Universidad de Navarra
Pamplona, Spain

In Partnership with:

Clinical Care Options, LLC 

Supported by educational grants from:

Amgen; Janssen Biotech, Inc. administered by Janssen Scientific Affairs, LLC.; Karyopharm Therapeutics Inc.; Pfizer, Inc.; Regeneron Pharmaceuticals, Inc.; Takeda Pharmaceuticals U.S.A., Inc.